S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
NASDAQ:CMMB

Chemomab Therapeutics (CMMB) Stock Price, News & Analysis

$0.68
+0.01 (+1.48%)
(As of 02/29/2024 ET)
Today's Range
$0.65
$0.69
50-Day Range
$0.48
$0.75
52-Week Range
$0.42
$1.90
Volume
37,317 shs
Average Volume
305,030 shs
Market Capitalization
$7.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Chemomab Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
921.9% Upside
$7.00 Price Target
Short Interest
Healthy
0.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of Chemomab Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.20) to ($1.40) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.52 out of 5 stars


CMMB stock logo

About Chemomab Therapeutics Stock (NASDAQ:CMMB)

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

CMMB Stock Price History

CMMB Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
US Stocks Gain; Producer Prices Fall In October
Chemomab Reports Fast Track Designation For CM-101 - Quick Facts
Chemomab Therapeutics GAAP EPS of $0.017
Chemomab Therapeutics files for $200M mixed shelf
See More Headlines
Receive CMMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
2/29/2024
Next Earnings (Confirmed)
3/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CMMB
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+921.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-27,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.11 per share

Miscellaneous

Free Float
9,734,000
Market Cap
$7.57 million
Optionable
Not Optionable
Beta
0.28
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Adi Mor George Ph.D. (Age 42)
    Co-Founder, Chief Scientific Officer, CEO & Executive Director
    Comp: $435.4k
  • Ms. Sigal Fattal CPA (Age 53)
    M.B.A., Chief Financial Officer
    Comp: $258k
  • Barbara Lindheim
    Consulting Vice President of Investor & Public Relations, Strategic Communications
  • Dr. Matthew B. Frankel M.B.A. (Age 54)
    M.D., Chief Medical Officer & VP of Drug Development














CMMB Stock Analysis - Frequently Asked Questions

Should I buy or sell Chemomab Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chemomab Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CMMB shares.
View CMMB analyst ratings
or view top-rated stocks.

What is Chemomab Therapeutics' stock price target for 2024?

3 brokerages have issued 12 month target prices for Chemomab Therapeutics' stock. Their CMMB share price targets range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 921.9% from the stock's current price.
View analysts price targets for CMMB
or view top-rated stocks among Wall Street analysts.

How have CMMB shares performed in 2024?

Chemomab Therapeutics' stock was trading at $0.51 at the start of the year. Since then, CMMB stock has increased by 34.3% and is now trading at $0.6850.
View the best growth stocks for 2024 here
.

Are investors shorting Chemomab Therapeutics?

Chemomab Therapeutics saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 37,600 shares, an increase of 15.7% from the January 31st total of 32,500 shares. Based on an average daily trading volume, of 268,700 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.4% of the company's stock are short sold.
View Chemomab Therapeutics' Short Interest
.

When is Chemomab Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our CMMB earnings forecast
.

How were Chemomab Therapeutics' earnings last quarter?

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) issued its quarterly earnings results on Thursday, November, 11th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.24.

How do I buy shares of Chemomab Therapeutics?

Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CMMB) was last updated on 3/1/2024 by MarketBeat.com Staff